Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more. It is an elite group of stocks recognized for their quality and consistency over time.That doesn’t mean their shares won’t fall. In fact, many of the high-yield Dividend Aristocrats below are down in 2024 or have fallen over the past year. What separates them from other similarly situated stocks, though, is thei ...

Earnings Announcement - AbbVie will announce its Q2 2024 financial results on July 25, 2024, before the market opens [1] - The earnings conference call will be webcast live at 8 a.m. Central time and accessible via AbbVie's Investor Relations website [1] - An archived edition of the session will be available later on the same day [1] Company Overview - AbbVie's mission is to discover and deliver innovative medicines and solutions for serious health issues [2] - The company focuses on key therapeutic areas including immunology, oncology, neuroscience, and eye care [2] - AbbVie also offers products and services through its Allergan Aesthetics portfolio [2]

One of the most important sectors in any country’s economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results. These companies have to move past the clinical trials and then prove that their drug or treatment is effective and safe.There are times when many of these candidates hit a dead wall, and the investment and research both go in vain. But if the company proves its worth, the rewards will be significant. This is why it takes a ...

Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years.Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%. Dividend stocks are more resilient, so this outperformance is even greater during market volatility. This is great, since the markets are stil ...

These reliable dividend payers are no-brainer buys right now.It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago.A buoyant stock market makes it harder to find compelling investment opportunities, but not if you know where to look. With artificial intelligence-related businesses absorbing most investors ...

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending granting conditional marketing authorization for the expanded use of its drug Tepkinly (epcoritamab) for treating relapsed/refractory follicular lymphoma (R/R FL).AbbVie is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with R/R FL after two or more prior therapies. The European Commission’s decis ...

Core Points - AbbVie has announced the appointment of Robert A. Michael as the new CEO, succeeding Richard A. Gonzalez, who will now serve as executive chairman [1][2] - Robert A. Michael has extensive experience in various leadership roles within AbbVie, including president and chief operating officer, and has been part of the Executive Leadership Team for many years [2][3] - The transition in leadership is aimed at continuing AbbVie's mission to deliver innovative medicines and to drive the next phase of growth for the company [3][4] Company Overview - AbbVie's mission focuses on discovering and delivering innovative medicines that address serious health issues and future medical challenges across key therapeutic areas such as immunology, oncology, neuroscience, and eye care [4]

These stocks could be ideal for investors in their golden years.Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%).A Dividend King poised for growthKeith Speight ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”).The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383.TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. In ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyPositive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyNORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) ...